GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Catheter Precision Inc (AMEX:VTAK) » Definitions » ROE %

Catheter Precision (Catheter Precision) ROE % : -12.43% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Catheter Precision ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Catheter Precision's annualized net income for the quarter that ended in Dec. 2023 was $-2.68 Mil. Catheter Precision's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $21.53 Mil. Therefore, Catheter Precision's annualized ROE % for the quarter that ended in Dec. 2023 was -12.43%.

The historical rank and industry rank for Catheter Precision's ROE % or its related term are showing as below:

VTAK' s ROE % Range Over the Past 10 Years
Min: -463.5   Med: -138.39   Max: -104.36
Current: -315.13

During the past 8 years, Catheter Precision's highest ROE % was -104.36%. The lowest was -463.50%. And the median was -138.39%.

VTAK's ROE % is ranked worse than
96.41% of 808 companies
in the Medical Devices & Instruments industry
Industry Median: 0.25 vs VTAK: -315.13

Catheter Precision ROE % Historical Data

The historical data trend for Catheter Precision's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catheter Precision ROE % Chart

Catheter Precision Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial -114.08 -132.77 -144.00 -234.29 -463.50

Catheter Precision Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -299.83 -1,177.23 -21.14 -33.76 -12.43

Competitive Comparison of Catheter Precision's ROE %

For the Medical Devices subindustry, Catheter Precision's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Catheter Precision's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Catheter Precision's ROE % distribution charts can be found below:

* The bar in red indicates where Catheter Precision's ROE % falls into.



Catheter Precision ROE % Calculation

Catheter Precision's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-70.572/( (9.26+21.192)/ 2 )
=-70.572/15.226
=-463.50 %

Catheter Precision's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-2.676/( (21.867+21.192)/ 2 )
=-2.676/21.5295
=-12.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Catheter Precision  (AMEX:VTAK) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-2.676/21.5295
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-2.676 / 0.512)*(0.512 / 31.8035)*(31.8035 / 21.5295)
=Net Margin %*Asset Turnover*Equity Multiplier
=-522.66 %*0.0161*1.4772
=ROA %*Equity Multiplier
=-8.41 %*1.4772
=-12.43 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-2.676/21.5295
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-2.676 / -2.676) * (-2.676 / -10.388) * (-10.388 / 0.512) * (0.512 / 31.8035) * (31.8035 / 21.5295)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.2576 * -2028.91 % * 0.0161 * 1.4772
=-12.43 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Catheter Precision ROE % Related Terms

Thank you for viewing the detailed overview of Catheter Precision's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Catheter Precision (Catheter Precision) Business Description

Traded in Other Exchanges
Address
1670 Highway 160 West, Suite 205, Fort Mill, SC, USA, 29708
Catheter Precision Inc Formerly Ra Medical Systems Inc is a commercial-stage medical device company whose business comprises of the design, manufacture and sale of new medical technologies in the field of cardiac electrophysiology, or EP. Its product, View into Ventricular Onset System or VIVO System which is a non invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. . It operates business as one segment which includes all activities related to the marketing, sales and development of medical technologies in the field of cardiac EP.
Executives
David A Jenkins director, officer: Executive Chairman of Board P.O. BOX 682838, PARK CITY UT 84068
Steven K Passey officer: Chief Financial Officer 3216 SOUTH HIGHLAND DRIVE, SUITE 200, SALT LAKE CITY UT 84117
James Joseph Caruso director 28 FIRST AVE, SEASIDE PARK NJ 08752
Brian Conn officer: Chief Financial Officer MICROISLET, INC., 6370 NANCY RIDGE DRIVE, SUITE 112, SAN DIEGO CA 92121
Andrew C. Jackson officer: CFO & Secretary 11988 EL CAMINO REAL STE. 650, SAN DIEGO CA 92130
Jonathan Will Mcguire director, officer: Chief Executive Officer 96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Susanne Meline director P.O. BOX 515381, #86506, LOS ANGELES CA 90051
Martin J Colombatto director
Richard Jr Mejia director 2200 FARADAY AVENUE, SUITE 100, CARLSBAD CA 92008
William R Enquist director 11810 WILLS ROAD, ALPHARETTA GA 30009
Joan Stafslien director CAREFUSION CORPORATION, 3750 TORREY VIEW COURT, SAN DIEGO CA 92130
Daniel Horwood officer: General Counsel C/O RA MEDICAL SYTEMS, INC., 2070 LAS PALMAS DRIVE, CARLSBAD CA 92011
Jeffrey J Kraws officer: Co-President 3985 RESEARCH PARK DRIVE, ANN ARBOR MI 48108
Dean Irwin director, 10 percent owner, officer: See Remarks C/O RA MEDICAL SYSTEMS, INC., 2070 LAS PALMAS DRIVE, CARLSBAD CA 92011
Martin Burstein 10 percent owner C/O RA MEDICAL SYSTEMS, INC., 2070 LAS PALMAS DRIVE, CARLSBAD CA 92011